Market News & Trends
Catalent Completes Acquisition of Gene Therapy Leader for $1.2 Billion
Catalent, Inc. recently announced it has completed the $1.2-billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies.…
CureVac Enters Into Exclusive Sponsored Research Agreement
CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, recently announced it has entered into a sponsored research agreement (SRA) with…
Precision Therapeutics’ Helomics Division Selected by AccuGenomics as Preferred Lab Partner
Precision Therapeutics Inc. recently announced its Helomics division has been selected as the preferred laboratory to provide laboratory services for the recently funded National Institute…
Saama Challenges Analytics Industry to Guarantee Data Platforms to Help Accelerate Drug Development
Saama Technologies, Inc. recently issued a call-to-action on Clinical Trials Day urging the analytics industry to commit to timely deployment of solutions for biopharmaceutical companies…
Owlstone Medical Enters Strategic Collaboration With Actelion
Owlstone Medical recently announced a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader…
Crinetics Pharmaceuticals Initiates Phase 1 Study for Treatment of Neuroendocrine Tumors
Crinetics Pharmaceuticals, Inc. recently announced the initiation of a Phase 1, double-blind, randomized, placebo-controlled, single- and multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics…
BioCryst’s Oral Drug Meets Primary Endpoint in Phase 3
BioCryst Pharmaceuticals, Inc. recently announced that the randomized (n=121), double-blind, placebo-controlled, Phase 3 APeX-2 trial of once-daily, oral BCX7353 for the prevention of hereditary angioedema…
WuXi STA & Dizal Pharmaceutical Sign Agreement
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, recently announced a strategic partnership.
Mercia Invests in Transdermal Drug Delivery Specialist
Medherant Limited, the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch technology, recently announced a new $2.5-million investment.
Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing & Supply
Catalent (Booth 3101) recently announced it will launch its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologic drugs at the…
Bayer Launches PHAB Awards With up to $1 Million in Grants
Bayer U.S recently announced the launch of the PHAB Awards to support clinical research in pulmonary hypertension, with a focus on pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Yamo Pharmaceuticals Presents Results from Phase 2 Study
Yamo Pharmaceuticals, LLC recently announced the presentation of results from a Phase 2 study with L1-79 in the treatment of ASD. A poster, titled An…
Elligo Health Research Launches Novel IntElligo Research Stack Clinical Technology
Elligo Health Research recently announced the launch of its innovative IntElligo Research Stack clinical technology. This standards-based technology platform, which powers the System of Accelerated…
ProBioGen & Vaccitech Sign License Agreement
ProBioGen AG and Vaccitech, Ltd. jointly announced signing a license agreement in which Vaccitech will gain access to ProBioGen’s proprietary technology platform based on the…
Road Ahead Still Difficult for Biosimilar Producers in the US Despite New FDA Guidance on Interchangeability
Following news that the FDA has finalized its guidance on interchangeable biosimilars, Rose Joachim, PhD, Senior Immunology Pharma Analyst at GlobalData, a leading data and…
Codexis Announces CodeEvolver Technology Transfer & License Agreement With Global Pharmaceutical Leader
Codexis, Inc. recently announced the signing of a CodeEvolver platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive license…
Adaptimmune & Alpine Immune Sciences Announce Collaboration & License Agreement
Adaptimmune Therapeutics plc and Alpine Immune Sciences, Inc. recently announced a collaboration and license agreement to develop next-generation SPEAR T-cell products that incorporate Alpine’s secreted…
Bone Sci Bio Presents Breakthrough Solutions for Bone Healing
Bone Sci Bio introduces PeptOss, a novel solution for bone treatment. The new product promotes formation and repair of bone tissue and enables controlled delivery of drugs, such as antibiotics or chemotherapy, directly to the bone, for various orthopedic and dental applications.
Cybrexa Therapeutics’ alphalex Platform Enables Tumor Targeting of Multiple PARP Inhibitors
Cybrexa Therapeutics recently announced preclinical data supporting the potential of its proprietary alphalex technology platform.
Caris Life Sciences Receives FDA Breakthrough Device Designation
Caris Life Sciences recently announced the US FDA has granted Breakthrough Device designation for the company’s MI Transcriptome companion diagnostic (CDx) test. Designed to detect…
